Provectus Biopharmaceuticals
PVCT
PVCT was delisted on the 13th of October, 2016.
39 hedge funds and large institutions have $6.13M invested in Provectus Biopharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
8% more funds holding
Funds holding: 36 → 39 (+3)
1% less ownership
Funds ownership: 6.21% → 5.22% (-1%)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
51% less capital inflows, than outflows
Capital inflows: $1.04M | Capital outflows: $2.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$493K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$419K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$30.7K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.9K |
| 5 |
Virtu KCG Holdings
New York
|
+$25.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.32M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$663K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$41K |
| 4 |
Renaissance Technologies
New York
|
-$25.5K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$20.5K |
PVCT Hedge Fund Activity: Q3 2015 in Review
39 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q3 2015, worth a combined $6.13M — down 7.7% from $6.64M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PVCT positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 9 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $493K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.32M sold.
- 39 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q3 2015, up from 36 in Q2 2015.
- Funds reported $6.13M of Provectus Biopharmaceuticals stock for Q3 2015, down 7.7% quarter-over-quarter.
- 6 funds opened new Provectus Biopharmaceuticals positions in Q3 2015 and 3 closed out, a net change of +3 holders.
- The largest Provectus Biopharmaceuticals buyer in Q3 2015 was Goldman Sachs, an estimated $493K added.
- The largest Provectus Biopharmaceuticals seller in Q3 2015 was Susquehanna International Group, an estimated $1.32M sold.
Based on aggregated 13F filings for Q3 2015.